Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
APX3330
Inflammatory Bowel Disease 2020
Filter by:
The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease
APX3330
Drug Discovery Today 2020
Phentolamine Mesylate Ophthalmic Solution Provides Long Lasting Pupil Modulation and Improves Visual Acuity
NYXOL
Presented at the Association for Research in Vision and Ophthalmology (Online Video Presentation)
Phentolamine Mesylate Ophthalmic Solution Reduces Time to Recovery of Medically-Induced Mydriasis in a Phase 2 Trial
NYXOL
Presented at the Association for Research in Vision and Ophthalmology (Online Video Presentation)
Ocuphire Pharma – Innovation Showcase
Conference Video Presentations
Presented at the Southeastern Educational Congress of Optometry – Ophthalmology Innovation Summit (Atlanta)
A Phase 1 Study of the APE1 Protein Inhibitor APX3330 in Patients with Advanced Solid Tumors
APX3330
Presented at the American Society of Clinical Oncology (Chicago)
Ocuphire Pharma – Innovation Showcase
Conference Video Presentations
Presented at the American Society of Cataract and Refractive Surgery – Ophthalmology Innovation Summit (San Diego)
APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats
APX3330
Aging and Disease 2018
Phentolamine Mesylate Ophthalmic Solution Once Daily Reduces Pupil Diameter and Improves Night Vision Disturbances
NYXOL
Presented at the American Association of Ophthalmology Meeting (Chicago)
